James M Lenhard

James M Lenhard

UNVERIFIED PROFILE

Are you James M Lenhard?   Register this Author

Register author
James M Lenhard

James M Lenhard

Publications by authors named "James M Lenhard"

Are you James M Lenhard?   Register this Author

14Publications

293Reads

26Profile Views

Intestinal serine protease inhibition increases FGF21 and improves metabolism in obese mice.

Am J Physiol Gastrointest Liver Physiol 2019 May 28;316(5):G653-G667. Epub 2019 Mar 28.

Cardiovascular and Metabolic Disease Discovery, Janssen R&D, LLC, Spring House, Pennsylvania.

View Article

Download full-text PDF

Source
https://www.physiology.org/doi/10.1152/ajpgi.00404.2018
Publisher Site
http://dx.doi.org/10.1152/ajpgi.00404.2018DOI Listing
May 2019

A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus.

Pharmacogenet Genomics 2016 Feb;26(2):53-65

aNeuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville, New Jersey bCVM Therapeutic Area, Janssen Research & Development, LLC, Spring House, Pennsylvania cPerlegen Sciences, Mountain View, California dAthanasiou Consulting, LLC, Fond du Lac, Wisconsin, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000185DOI Listing
February 2016

Thioredoxin-mimetic peptide CB3 lowers MAPKinase activity in the Zucker rat brain.

Redox Biol 2014 9;2:447-56. Epub 2014 Jan 9.

Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904 Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.redox.2013.12.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949098PMC
June 2015

4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.

Bioorg Med Chem Lett 2013 Dec 9;23(24):6773-6. Epub 2013 Oct 9.

Cardiovascular and Metabolism Research, Janssen Research and Development, LLC, Welsh & McKean Roads, Spring House, PA 19477, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0960894X130118
Publisher Site
http://dx.doi.org/10.1016/j.bmcl.2013.09.096DOI Listing
December 2013

Lipogenic enzymes as therapeutic targets for obesity and diabetes.

Authors:
James M Lenhard

Curr Pharm Des 2011 ;17(4):325-31

Cardiovascular and Metabolic Research, Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Springhouse, PA 19477, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138161211795164185DOI Listing
July 2011

2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV.

Bioorg Med Chem Lett 2005 Dec 15;15(23):5257-61. Epub 2005 Sep 15.

Department of Medicinal Chemistry, GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.08.050DOI Listing
December 2005

Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.

Biochem Biophys Res Commun 2004 Nov;324(1):92-7

Department of Metabolic Diseases, GlaxoSmithKline Inc., Research Triangle Park, NC 27709, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0006291X0402064
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2004.09.021DOI Listing
November 2004

Structure-based design of potent retinoid X receptor alpha agonists.

J Med Chem 2004 Apr;47(8):2010-29

GlaxoSmithKline Research and Development, 5 Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm030565gDOI Listing
April 2004

Preclinical developments in type 2 diabetes.

Adv Drug Deliv Rev 2002 Nov;54(9):1199-212

Department of Metabolic Diseases, GlaxoSmithKline Inc, 5 Moore Drive, Research Triangle Park, NC 27709, USA.

View Article

Download full-text PDF

Source
November 2002

Select HIV protease inhibitors alter bone and fat metabolism ex vivo.

J Biol Chem 2002 May 5;277(22):19247-50. Epub 2002 Apr 5.

Department of Metabolic Diseases, GlaxoSmithKline Inc., Research Triangle Park, North Carolina 27709, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.C200069200
Publisher Site
http://dx.doi.org/10.1074/jbc.C200069200DOI Listing
May 2002